Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Phase 3

Completed

Conditions: Neoplasms, Unknown Primary

Interventions: Drug: Gemcitabine
Drug: Etoposide
Drug: Paclitaxel
Drug: Irinotecan
Drug: Carboplatin

First Posted Date: 2005-09-19

Last Posted Date: 2013-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 198

Registration Number: NCT00193596

Locations: 🇺🇸
Tower Oncology, Beverly Hills, California, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Jackson Oncology Associates, Jackson, Mississippi, United States

and more 28 locations

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2010-06-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00193284

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00191230

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 77

Registration Number: NCT00191256

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States